Loading...

Stock Snapshot

{{stockQuote.companyFullName}}
{{stockQuote.quoteInfo}}
{{stockQuote.valueFormatted}}
{{getFormattedValue(stockQuote.changesValueFormatted)}} ({{getFormattedValue(stockQuote.changesPercentFormatted)}}%)
{{getFormattedDateTime(stockQuote.delayDate)}}
{{stockQuote.onlyDateFormatted}} (At Close)
Previous Close
{{todayDetailedInformation.previousClose}}
Volume
{{todayDetailedInformation.volume}}
Today’s Open
{{todayDetailedInformation.todaysOpen}}
Average Volume (10 days)
{{detailQuote.averageVolume}}
Day's Range
{{todayDetailedInformation.todaysLow}} - {{todayDetailedInformation.todaysHigh}}
Market Cap
{{detailQuote.marketCap}}
52 Week Range
{{detailQuote.weekLow}} -{{detailQuote.weekHigh}}
Total Shares Outstanding
{{detailQuote.totalSharesOutstanding}}
More Info

Latest Company Reports

Latest Press Releases

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

{{getFormattedDate('2026-08-20T09:15:00.0000000')}}

Company Profile

Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Industry